Christos Melidis1, Walther R Bosch2, Joanna Izewska3, Elena Fidarova4, Eduardo Zubizarreta4, Kenneth Ulin5, Satoshi Ishikura6, David Followill7, James Galvin8, Annette Haworth9, Deidre Besuijen10, Catharine H Clark, Clark H Clark11, Elizabeth Miles12, Edwin Aird12, Damien C Weber13, Coen W Hurkmans14, Dirk Verellen15. 1. European Organization for the Research and Treatment of Cancer-Radiation Oncology Group (EORTC-ROG), Radiation Therapy Quality Assurance (RTQA), Brussels, Belgium. Electronic address: christos.melidis@eortc.be. 2. Washington University, representing Advanced Technology Consortium, Radiation Oncology, St. Louis, Missouri. 3. Dosimetry Laboratory, International Atomic Energy Agency, Vienna, Austria. 4. Applied Radiation Biology and Radiotherapy Section, International Atomic Energy Agency, Vienna, Austria. 5. Department of Radiation Oncology, University of Massachusetts Medical School, Representing Quality Assurance Review Center, Worcester, Massachusetts. 6. Department of Radiation Oncology, Juntendo University, Representing Japan Clinical Oncology Group, RTQA, Tokyo, Japan. 7. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Representing Radiological Physics Center, RTQA, Houston, Texas. 8. Department of Radiation Oncology, Thomas Jefferson University, Representing Radiation Therapy Oncology Group, RTQA, Philadelphia, Pennsylvania. 9. Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, representing TransTasman Radiation Oncology Group (TROG) Cancer Research, Newcastle, Australia. 10. North West Cancer Centre, Representing TROG Cancer Research, Newcastle, Australia. 11. Department of Medical Physics, St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey and National Physical Laboratory, Teddington, Middlesex, representing Radiation Therapy Trials Quality Assurance (RTTQA), United Kingdom. 12. Mount Vernon Cancer Centre, Northwood, Middlesex representing RTTQA, United Kingdom. 13. Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland, Representing the EORTC-ROG, RTQA, Brussels, Belgium. 14. Catharina Hospital, Eindhoven, The Netherlands, Representing EORTC-ROG, RTQA, Brussels, Belgium. 15. Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Abstract
PURPOSE: To review the various radiation therapy quality assurance (RTQA) procedures used by the Global Clinical Trials RTQA Harmonization Group (GHG) steering committee members and present the harmonized RTQA naming conventions by amalgamating procedures with similar objectives. METHODS AND MATERIALS: A survey of the GHG steering committee members' RTQA procedures, their goals, and naming conventions was conducted. The RTQA procedures were classified as baseline, preaccrual, and prospective/retrospective data capture and analysis. After all the procedures were accumulated and described, extensive discussions took place to come to harmonized RTQA procedures and names. RESULTS: The RTQA procedures implemented within a trial by the GHG steering committee members vary in quantity, timing, name, and compliance criteria. The procedures of each member are based on perceived chances of noncompliance, so that the quality of radiation therapy planning and treatment does not negatively influence the trial measured outcomes. A comparison of these procedures demonstrated similarities among the goals of the various methods, but the naming given to each differed. After thorough discussions, the GHG steering committee members amalgamated the 27 RTQA procedures to 10 harmonized ones with corresponding names: facility questionnaire, beam output audit, benchmark case, dummy run, complex treatment dosimetry check, virtual phantom, individual case review, review of patients' treatment records, and protocol compliance and dosimetry site visit. CONCLUSIONS: Harmonized RTQA harmonized naming conventions, which can be used in all future clinical trials involving radiation therapy, have been established. Harmonized procedures will facilitate future intergroup trial collaboration and help to ensure comparable RTQA between international trials, which enables meta-analyses and reduces RTQA workload for intergroup studies.
PURPOSE: To review the various radiation therapy quality assurance (RTQA) procedures used by the Global Clinical Trials RTQA Harmonization Group (GHG) steering committee members and present the harmonized RTQA naming conventions by amalgamating procedures with similar objectives. METHODS AND MATERIALS: A survey of the GHG steering committee members' RTQA procedures, their goals, and naming conventions was conducted. The RTQA procedures were classified as baseline, preaccrual, and prospective/retrospective data capture and analysis. After all the procedures were accumulated and described, extensive discussions took place to come to harmonized RTQA procedures and names. RESULTS: The RTQA procedures implemented within a trial by the GHG steering committee members vary in quantity, timing, name, and compliance criteria. The procedures of each member are based on perceived chances of noncompliance, so that the quality of radiation therapy planning and treatment does not negatively influence the trial measured outcomes. A comparison of these procedures demonstrated similarities among the goals of the various methods, but the naming given to each differed. After thorough discussions, the GHG steering committee members amalgamated the 27 RTQA procedures to 10 harmonized ones with corresponding names: facility questionnaire, beam output audit, benchmark case, dummy run, complex treatment dosimetry check, virtual phantom, individual case review, review of patients' treatment records, and protocol compliance and dosimetry site visit. CONCLUSIONS: Harmonized RTQA harmonized naming conventions, which can be used in all future clinical trials involving radiation therapy, have been established. Harmonized procedures will facilitate future intergroup trial collaboration and help to ensure comparable RTQA between international trials, which enables meta-analyses and reduces RTQA workload for intergroup studies.
Authors: S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle Journal: Br J Radiol Date: 2015-04-15 Impact factor: 3.039
Authors: Thomas J FitzGerald; Maryann Bishop-Jodoin; David S Followill; James Galvin; Michael V Knopp; Jeff M Michalski; Mark A Rosen; Jeffrey D Bradley; Lalitha K Shankar; Fran Laurie; M Giulia Cicchetti; Janaki Moni; C Norman Coleman; James A Deye; Jacek Capala; Bhadrasain Vikram Journal: Int J Radiat Oncol Biol Phys Date: 2015-10-24 Impact factor: 7.038
Authors: Kelsey L Corrigan; Stephen Kry; Rebecca M Howell; Ramez Kouzy; Joseph Abi Jaoude; Roshal R Patel; Anuja Jhingran; Cullen Taniguchi; Albert C Koong; Mary Fran McAleer; Paige Nitsch; Claus Rödel; Emmanouil Fokas; Bruce D Minsky; Prajnan Das; C David Fuller; Ethan B Ludmir Journal: Radiother Oncol Date: 2021-11-25 Impact factor: 6.280
Authors: Catharine H Clark; Edwin G A Aird; Steve Bolton; Elizabeth A Miles; Andrew Nisbet; Julia A D Snaith; Russell A S Thomas; Karen Venables; David I Thwaites Journal: Br J Radiol Date: 2015-09-02 Impact factor: 3.039
Authors: Jean M Moran; Andrea Molineu; Jon J Kruse; Mark Oldham; Robert Jeraj; James M Galvin; Jatinder R Palta; Arthur J Olch Journal: J Appl Clin Med Phys Date: 2018-06-29 Impact factor: 2.102
Authors: David B Landau; Laura Hughes; Angela Baker; Andrew T Bates; Michael C Bayne; Nicholas Counsell; Angel Garcia-Alonso; Susan V Harden; Jonathan D Hicks; Simon R Hughes; Marianne C Illsley; Iftekhar Khan; Virginia Laurence; Zafar Malik; Helen Mayles; William Philip M Mayles; Elizabeth Miles; Nazia Mohammed; Yenting Ngai; Emma Parsons; James Spicer; Paula Wells; Dean Wilkinson; John D Fenwick Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-28 Impact factor: 7.038
Authors: A De Bruycker; A Spiessens; P Dirix; N Koutsouvelis; I Semac; N Liefhooghe; A Gomez-Iturriaga; W Everaerts; F Otte; A Papachristofilou; M Scorsetti; M Shelan; S Siva; F Ameye; M Guckenberger; R Heikkilä; P M Putora; A Zapatero; A Conde-Moreno; F Couñago; F Vanhoutte; E Goetghebeur; D Reynders; T Zilli; P Ost Journal: BMC Cancer Date: 2020-05-12 Impact factor: 4.430